Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Genetic alterations that potentiate PI3K signaling are frequent in prostate cancer, yet how different genetic drivers of the PI3K cascade contribute to prostate cancer is unclear. Here, we report PIK3CA mutation/amplification correlates with poor survival of patients with prostate cancer. To interrogate the requirement of different PI3K genetic drivers in prostate cancer, we employed a genetic approach to mutate Pik3ca in mouse prostate epithelium. We show Pik3caH1047R mutation causes p110α-dependent invasive prostate carcinoma in vivo. Furthermore, we report that PIK3CA mutation and PTEN loss coexist in patients with prostate cancer and can cooperate in vivo to accelerate disease progression via AKT–mTORC1/2 hyperactivation. Contrasting single mutants that slowly acquire castration-resistant prostate cancer (CRPC), concomitant Pik3ca mutation and Pten loss caused de novo CRPC. Thus, Pik3ca mutation and Pten deletion are not functionally redundant. Our findings indicate that PIK3CA mutation is an attractive prognostic indicator for prostate cancer that may cooperate with PTEN loss to facilitate CRPC in patients. Significance: We show PIK3CA mutation correlates with poor prostate cancer prognosis and causes prostate cancer in mice. Moreover, PIK3CA mutation and PTEN loss coexist in prostate cancer and can cooperate in vivo to accelerate tumorigenesis and facilitate CRPC. Delineating this synergistic relationship may present new therapeutic/prognostic approaches to overcome castration/PI3K–AKT–mTORC1/2 inhibitor resistance. Cancer Discov; 8(6); 764–79. ©2018 AACR. See related commentary by Triscott and Rubin, p. 682. This article is highlighted in the In This Issue feature, p. 663
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 1×
“Indeed, loss of PTEN, a negative regulator of the PI3K pathway, is estimated to occur in 40-50% of prostate cancer patients(7,8).”
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
García-Martínez, J. M., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20081668 · Cited by 907 · cited 1×
“5 Myc down-regulated gene-1 (NDRG1/DRG1/CAP43)(6).”
Mutation of the PIK3CA oncogene in human cancers
Karakas, B., Bachman, K. E., & Park, B. H. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602970 · Cited by 505 · cited 14×
“6%) domains, and previously reported hotspot mutations in exon 9 (E542K, E545K) and 20 (H1047R)(10-12,15) were most frequent (Fig.”
InfluentialFerraldeschi, R., Nava Rodrigues, D., Riisnaes, R., Miranda, S., Figueiredo, I., Rescigno, P., Ravi, P., Pezaro, C., Omlin, A., Lorente, D., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.027 · Cited by 268 · cited 1×
“PTEN loss is widely reported to correlate with resistance to androgen deprivation therapy in prostate cancer patients and mice(9,32,33).”
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Self-citationThe PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 616
Self-citationPapa, A., & Pandolfi, P. P. (2019) · Biomolecules · doi:10.3390/biom9040153 · Cited by 303
Organoid-on-a-chip model of human ARPKD reveals mechanosensing pathomechanisms for drug discovery
Hiratsuka, K., Miyoshi, T., Kroll, K. T., Gupta, N. R., Valerius, M. T., Ferrante, T., Yamashita, M., Lewis, J. A., & Morizane, R. (2022) · Science Advances · doi:10.1126/sciadv.abq0866 · Cited by 140
Metadata
- Authors
- Pearson, H. B., Li, J., Meniel, V. S., Fennell, C. M., Waring, P., Montgomery, K. G., Rebello, R. J., Macpherson, A. A., Koushyar, S., Furic, L., Cullinane, C., Clarkson, R. W., Smalley, M. J., Simpson, K. J., Phesse, T. J., Shepherd, P. R., Humbert, P. O., Sansom, O. J., & Phillips, W. A.
- Venue
- Cancer Discovery
- Published
- 2018-05-31
- Volume
- 8
- Issue
- 6
- Pages
- 764-779
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2790119669
- Cited by
- 132
- References
- 6
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-0867
- The paper
- Pearson, H. B., Li, J., Meniel, V. S., Fennell, C. M., Waring, P., Montgomery, K. G., Rebello, R. J., Macpherson, A. A., Koushyar, S., Furic, L., Cullinane, C., Clarkson, R. W., Smalley, M. J., Simpson, K. J., Phesse, T. J., Shepherd, P. R., Humbert, P. O., Sansom, O. J., & Phillips, W. A. (2018). Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-0867
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.